NCT00002053已完成不适用
A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Fisons
- 试验地点
- 2
研究概览
简要总结
To evaluate and compare the safety, tolerability, and efficacy of biweekly administration of aerosol pentamidine versus placebo when used as a prophylactic agent in patients who have recovered from their first episode of AIDS-associated Pneumocystis carinii pneumonia (PCP).
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Zidovudine (AZT). If AZT is started during the study, patients must have received = or > 15 days of aerosol pentamidine before beginning AZT.
- •Prior Medication:
- •Zidovudine (AZT). If AZT began prior to study entry, patients must have received = or > 15 days of AZT before beginning aerosol pentamidine.
排除标准
- •Co-existing Condition:
- •Patients with the following are excluded:
- •Requiring ongoing active therapy for an opportunistic infection (O.I.) at time of entry or those with either of the following AIDS-defining O.I.'s prior to entry:
- •Toxoplasmosis.
- •Cryptococcosis.
- •Transfusion dependent (requiring blood transfusion more than once per month). The last transfusion cannot have been given within 7 days of study entry.
- •Pulmonary Kaposi's sarcoma (KS).
- •Uncontrolled asthma.
- •Active therapy for tuberculosis.
- •Patients with the following are excluded:
- •Requiring ongoing active therapy for an opportunistic infection (O.I.) at time of entry or those with either of the following AIDS-defining O.I.'s prior to entry:
- •Toxoplasmosis.
- •Cryptococcosis.
- •Transfusion dependent (requiring blood transfusion more than once per month). The last transfusion cannot have been given within 7 days of study entry.
- •Pulmonary Kaposi's sarcoma (KS).
- •Uncontrolled asthma.
- •Prior Medication:
- •Excluded within 30 days of study entry:
- •Antiretroviral agents other than zidovudine (AZT).
- •Immunomodulating agents.
- •Corticosteroids.
- •Active therapy for tuberculosis.
- •Patients must:
- •Have AIDS and recovered from their first episode of Pneumocystis carinii pneumonia (PCP).
- •Be at least 2 weeks and no more than 24 weeks status post therapy for acute PCP.
- •Have positive antibody to HIV by a Government-approved ELISA test kit, or confirmed Western blot test.
- •Adequate pulmonary function (vital capacity = or > 80 percent of predicted; forced expiratory volume (FEV), 1 s = or > 65 percent of total FEV; and corrected pulmonary diffusion capacity > 60 percent of predicted).
- •Free of acute medical problems.
- •Active substance abuse.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)Seasonal Allergic RhinitisHay FeverNCT01024608Teva Branded Pharmaceutical Products R&D, Inc.340
已完成
3 期
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)Rhinitis, Allergic, PerennialNCT01134705Teva Branded Pharmaceutical Products R&D, Inc.474
终止
2 期
Efficacy of Aerosal® in the Treatment of Sub-Obstructive Adenotonsillar Hypertrophy and Related DiseasesSleep Apnea, ObstructiveNCT01574885Tecno Sun SRL45
撤回
2 期
Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and SebopsoriasisInverse PsoriasisSebopsoriasisNCT01574872Tecno Sun SRL
已完成
不适用
The Safety and Effectiveness of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Who Have Had PCP BeforePneumonia, Pneumocystis CariniiHIV InfectionsNCT00002291Fisons